Prescriber Criteria Form HRM Low Impact 2025 PA Fax 1422-B v2 010125.docx High Risk Medications (Hrm) Criteria This HRM List applies to formulary drugs only. Prior Authorization applies only to patients 70 years of age or older Disopyramide, Disopyramide Extended Release (Norpace CR) Antiarrhythmic Antineoplastic Megestrol Tablets, Suspension (not including Megestrol ES Suspension 625mg/5ml) Antihistamine Carbinoxamine, Clemastine, Dexchlorpheniramine, Diphenhydramine Oral, Promethazine/Phenylephrine Dipyridamole Antiplatelet Antipsychotic-Antidepressant Perphenazine/Amitriptyline Combination Cardiovascular Digoxin (applies to greater than 0.125mg Daily) Estrogens Bijuva (estradiol/progesterone), Premarin Oral (conjugated estrogens oral), Conjugated Estrogen Synthetic A And B, Prempro, Premphase (conjugated estrogens/medroxyprogesterone acetate), Duavee (conjugated estrogens/bazedoxifene), estradiol oral, topical, esterified estrogens, estradiolnorethindrone oral, topical, estradiol-estradiol-norgestimate, estropipate, estradiollevonorgestrel Non-Steroidal Anti-Ketorolac Tromethamine Tablets Inflammatory **Coverage Determination** This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS Caremark at 1-855-633-7673. Please contact CVS Caremark at 1-866-785-5714 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of HRM Low Impact. Drug Name (select from list of drugs shown): Patient Name: Patient ID: Patient DOB: Patient Phone: Prescriber Name:

Please circle the appropriate answer for each question.					
1	The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored. Does	Yes	No		

State:

Prescriber Fax:

ICD Code(s):

Zip:

Prescriber Address:

Prescriber Phone:

City:

Diagnosis:

Prescriber	(or Authorized) Signature:	Date:	
, , ,	this form, I attest that the information provided is tion supporting this information is available for re-		
Comments			_
	e benefit of therapy with this prescribed medicati	on outweigh the potential risks for this	